·Launched rapid response program to target and develop top cardiovascular advocates in key EU countries to secure the European regulatory approval that enabled the entrance into the $375 MM market for post-myocardial infarction and heart failure for Novartis’ top selling drug, Diovan.
·Directed comprehensive stakeholder management program to secure commitments of $1.9 Billion in 2005 from major donor countries to assist African nations in purchasing Novartis’ anti-malarial drug, Coartem.
·Led all planning, outreach and implementation of a comprehensive Novartis corporate strategy to establish a leadership position with patient group partners who are key allies for Novartis’ global and country pharmaceutical brand teams.Outreach intitiatives resulted in the first time Novartis secured top 3 ranking among pharma company reputation surveys among Europe’s leading patient group organizations from 2004 to 2006.
·Led cross functional global and country team on the development of a globally supported strategy to optimally position Diovan in two guidance documents developed by the National Institute of Clinical Excellence (NICE) for myocardial infarction and hypertension which significantly shaped European payer and pricing considerations.
·Led the development and execution of a broad-based alliance strategy to optimally position a new hypertensive class in Renin Inhibition with major cardiovascular and renal advocacy organizations.These efforts ensured the external support needed for the regulatory and reimbursement approval in 2007 US and European approval of Novartis’ Tekturna as the first drug in this class valued at $1.5 Billion.